Green Biotech Fund Surges Past €150M Target

The BioEconomy Fund I is a global health fund that focuses on business-to-business (B2B) alternatives that substitute unsustainable products with scalable, cost-efficient options. It is backed by high-caliber institutional investors such as KfW Capital, Novo Holdings, Rentenbank, and Aurae Impact, along with new supporters ABN AMRO Bank and EIFO. The BioEconomy Fund I expects to reach an ambitious final close anticipated near its €200m hard cap.

Sander Slootweg, Managing Partner and co-founder of Forbion, stated, “Exceeding €150m in just over a year reflects the strength of our team and strategy and the confidence our investors have in our ability to execute. Their support for BioEconomy Fund I demonstrates the growing demand for scalable, cost-competitive biotech solutions that deliver both sustainability and strong returns.”